Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLQ | O75417 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901971 | 0.88 | MAPK1 (0.45) | KDM4ECYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL2725133 | 0.81 | POLQ (0.50) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14901970 | 0.81 | MAPK1 (0.41) | KDM4ECYP1A2CYP2C19DYRK1ALMNA | |
| SCHEMBL14889881 | 0.80 | MAPK1 (0.42) | KDM4ECYP1A2CYP2C19DYRK1ALMNA | |
| SCHEMBL15256554 | 0.77 | DYRK1A (0.54) | DYRK1ANPC1RAB9AMAPTPOLQ | |
| SCHEMBL18825226 | 0.76 | MAPK1 (0.53) | KDM4ECYP1A2CYP2C19LMNAMAPT | |
| SCHEMBL13188759 | 0.76 | DYRK1A (0.58) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5183305 | 0.75 | DGAT1 (0.49) | DYRK1AMAPTDGAT1MAPK1 | |
| SCHEMBL1528983 | 0.75 | CA1 (0.61) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL24994318 | 0.75 | RXFP1 (0.54) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771345-B1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2771345-B1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME (US) | 2016-09-21 | — | — | EP | disclosed |
| US-9346825-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346825-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140378493-A1 | Fused Bicyclic Oxazolidinone CETP Inhibitor | MERCK SHARP & DOHME LLC | 2014-12-25 | — | — | US | disclosed |
| US-20140378493-A1 | Fused Bicyclic Oxazolidinone CETP Inhibitor | MERCK SHARP & DOHME LLC | 2014-12-25 | — | — | US | disclosed |
| US-8871738-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871738-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2771345-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
| WO-2013063217-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013063217-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378493-A1 | Fused Bicyclic Oxazolidinone CETP Inhibitor | CETP, MTTP, APOB | KDM4E 2743/4885CYP1A2 1621/4885CYP2D6 1905/4885 |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | CETP, MTTP, APOB | KDM4E 2743/4885CYP1A2 1621/4885CYP2D6 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.